|
|
Blood, 15 September 2008, Vol. 112, No. 6, pp. 2190-2198.
 Previous Article | Table of Contents | Next Article 
ASH 50TH ANNIVERSARY REVIEWS
Myeloproliferative disorders
Ross L. Levine1, and
D. Gary Gilliland24
1 Human Oncology and Pathogenesis Program, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY;
2 Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;
3 Howard Hughes Medical Institute, Harvard Stem Cell Institute, Boston, MA; and
4 Broad Institute of Harvard and MIT, Boston, MA
In 1951 William Dameshek classified polycythemia vera (PV), essential thombocytosis (ET), and primary myelofibrosis (PMF) as pathogenetically related myeloproliferative disorders (MPD). Subsequent studies demonstrated that PV, ET, and PMF are clonal disorders of multipotent hematopoietic progenitors. In 2005, a somatic activating mutation in the JAK2 nonreceptor tyrosine kinase (JAK2V617F) was identified in most patients with PV and in a significant proportion of patients with ET and PMF. Subsequent studies identified additional mutations in the JAK-STAT pathway in some patients with JAK2V617F– MPD, suggesting that constitutive activation of this signaling pathway is a unifying feature of these disorders. Although the discovery of mutations in the JAK-STAT pathway is important from a pathogenetic and diagnostic perspective, important questions remain regarding the role of this single disease allele in 3 related but clinically distinct disorders, and the role of additional genetic events in MPD disease pathogenesis. In addition, these observations provide a foundation for development of small molecule inhibitors of JAK2 that are currently being tested in clinical trials. This review will discuss our understanding of the pathogenesis of PV, ET, and PMF, the potential role of JAK2-targeted therapy, and the important unanswered questions that need to be addressed to improve clinical outcome.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. S. K. Potula, D. Wang, D. Van Quyen, N. K. Singh, V. Kundumani-Sridharan, M. Karpurapu, E. A. Park, W. C. Glasgow, and G. N. Rao
Src-dependent STAT-3-mediated Expression of Monocyte Chemoattractant Protein-1 Is Required for 15(S)-Hydroxyeicosatetraenoic Acid-induced Vascular Smooth Muscle Cell Migration
J. Biol. Chem.,
November 6, 2009;
284(45):
31142 - 31155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cankovic, L. Whiteley, R. C. Hawley, R. J. Zarbo, and D. Chitale
Clinical Performance of JAK2 V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory: Evaluation of Screening and Quantitation Methods
Am J Clin Pathol,
November 1, 2009;
132(5):
713 - 721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Cerrato, V. De Falco, and M. Santoro
Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets
J. Mol. Endocrinol.,
October 1, 2009;
43(4):
143 - 155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Wood, E. Chen, I. J. Donaldson, S. Hattangadi, K. A. Burke, M. A. Dawson, D. Miranda-Saavedra, H. F. Lodish, A. R. Green, and B. Gottgens
ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling
Blood,
August 27, 2009;
114(9):
1820 - 1830.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz, A. Porwit, N. L. Harris, M. M. Le Beau, E. Hellstrom-Lindberg, A. Tefferi, et al.
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Blood,
July 30, 2009;
114(5):
937 - 951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi, G. Masala, E. Antonioli, M. Chiara Susini, P. Guglielmelli, L. Pieri, L. Maggi, S. Caini, D. Palli, C. Bogani, et al.
Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Cancer Epidemiol. Biomarkers Prev.,
July 1, 2009;
18(7):
2068 - 2073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. G. Mullighan, J. Zhang, R. C. Harvey, J. R. Collins-Underwood, B. A. Schulman, L. A. Phillips, S. K. Tasian, M. L. Loh, X. Su, W. Liu, et al.
JAK mutations in high-risk childhood acute lymphoblastic leukemia
PNAS,
June 9, 2009;
106(23):
9414 - 9418.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Levine and M. Carroll
A Common Genetic Mechanism in Malignant Bone Marrow Diseases
N. Engl. J. Med.,
May 28, 2009;
360(22):
2355 - 2357.
[Full Text]
[PDF]
|
|
|
|
|
